Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.

@article{Horak1997RadioimmunotherapyTO,
  title={Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.},
  author={Eva M. Horak and Frank Hartmann and Kayhan Garmestani and Chuanchu Wu and Martin W. Brechbiel and Otto A. Gansow and Nicholas F. Landolfi and Thomas A. Waldmann},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={1997},
  volume={38 12},
  pages={1944-50}
}
UNLABELLED The specificity, toxicity and efficacy of lead (212Pb) radioimmunotherapy were evaluated in nude mice bearing the SK-OV-3 human ovarian tumor cell line expressing the HER2/neu proto-oncogene. METHODS The therapeutic agent used was the tumor-specific anti-HER2/neu monoclonal antibody AE1 conjugated to 212Pb, 212Bi being the daughter and thus the source of the alpha-particle and beta emissions. A bifunctional derivative of tetraazacyclododecanetetraacetic acid (p-SCN-Bz-DOTA) was… CONTINUE READING